The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Merck KGaA is edging closer to the SpringWorks deal, which was first rumoured in February, confirming late-stage negotiations at an estimated price of $47 per share – potentially valuing the deal at ...
Presented positive topline data from the pivotal Phase 2b ReNeu trial evaluating mirdametinib, an investigational oral MEK inhibitor, in pediatric and adult patients with neurofibromatosis type ...
SpringWorks Therapeutics is launching a new disease state education campaign at DesmoidTumors.com. The clinical-stage biotech, which is working on medicines to help patients suffering from rare ...
As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease drugmaker has attracted the attention of a biopharma bigwig from overseas.
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. & SAN MATEO, Calif. & STAMFORD, Conn.--(BUSINESS WIRE)--MapKure, LLC, BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE ...
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.76% By Investing.com - May 27, 2022 Investing.com – U.S. stocks were higher after the close on Friday, as gains in the ...
Reacting to press speculation, Merck KGaA has acknowledged that talks to buy US biotech SpringWorks are now in the late stages and are revolving around an offer of around $47 per share. Merck stressed ...
Nov 28 (Reuters) - SpringWorks Therapeutics' (SWTX.O), opens new tab drug for treating adult patients with a type of rare non-cancerous soft-tissue tumor will be sold in the U.S. at a list price of ...
NEW YORK--(BUSINESS WIRE)--SpringWorks Therapeutics, a mission-driven medicines company dedicated to developing innovative potential new treatments for underserved patient communities, announced its ...
FDA approved SpringWorks' mirdametinib for NF1 patients with symptomatic plexiform neurofibromas, granting a priority review voucher. In the Phase 2b trial, Gomekli showed a 41% ORR in adults and 52% ...
SpringWorks Therapeutics, Inc. SWTX expanded its existing clinical collaboration agreement with GSK GSK. The partnership is evaluating the combination of SpringWorks’ investigational oral gamma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results